CA-ONCLUSIVE
5.1.2022 16:10:12 CET | Business Wire | Press release
Today, leading technology investor Symphony Technology Group “STG” completes its acquisition of Kantar ’s Reputation Intelligence business, and with it announces the additional purchases of PRgloo and Onclusive . Together the three businesses merge to create a new global media monitoring, measurement, and workflow management partner for PR and communications.
The new standalone company will operate under the name ‘Onclusive’ reflecting the inclusive and scalable nature of its newly combined offer and its commitment to accelerating investment in tech-powered platforms and solutions.
The company builds on the consultative strengths and scale of Europe’s largest media monitoring and analysis provider, Kantar Reputation Intelligence; UK-based PRgloo’s industry-leading media relations and workflow management platform and US-based Onclusive’s AI technology and data science.
Commenting on the new company, Chief Commercial Officer of the newly-formed Onclusive, Petra Masinova explained: “We’ve always admired each other’s strengths and we’ve increasingly teamed up on programmes to help solve clients’ needs. Today we accelerate our natural evolution to become one company, amplifying our strengths and supporting our clients with leading insights, technology and expertise together under one roof.”
Dan Beltramo, Chief Innovation Officer of the new Onclusive , also praised the union: “Onclusive is a technology and innovation pioneer in media monitoring and analytics while Kantar Reputation Intelligence is a leader in customer service with top-tier European coverage and market-leading insights capabilities. It brings us scale and ambition for global leadership.”
Samantha Deeks, VP Customer Experience at new Onclusive added: “Building on PRgloo’s customer-centric design approach, we’re delighted to work with like-minded industry leaders to build a scalable and agile business; one which actively listens and responds to the needs of its clients as they navigate an increasingly complex communications environment.”
Managing Director at STG, J.T. Treadwell , said: “Last year STG made clear its intention to create a market leading insights and software company through the proposed acquisition of Kantar Reputation Intelligence. Completing that acquisition is a major first step and the additional capabilities brought by Onclusive and PRgloo widen the scope of our commitment to providing best-in-class solutions for PR and Communications teams, both now and in the future.”
Onclusive will serve more than 9,000 clients, including many of the world’s biggest brands, across 130 markets. The company has over 1,100 employees based in the USA, UK, Ireland, France, Italy, Spain, Germany and Australia.
Onclusive North America Managing Director, Sean O’Neal , continued: “Our clients were our matchmakers – they told us they wanted one trusted partner to help them access and integrate our combined best-in-class services. We listened and from today Onclusive will help every client – from small enterprises to multi-national public and private organisations – shape, manage and evaluate their communications strategies.”
From today, clients can access the new Onclusive’s full range of services, supporting them at every stage of the communications cycle. Existing services continue uninterrupted.
About Onclusive
Onclusive is a global partner for PR and Communications success. We bring together Kantar Reputation Intelligence, the largest media monitoring and measurement service in Europe, with the best-in-class tools of PRgloo, and Onclusive’s own powerful AI and data science. Our technology, insights and expertise make sense of the fractured, fast-moving media world, helping you manage, monitor and measure your communications activity. Elevate your performance and prove and improve your value with Onclusive on your side.
About STG Partners
STG is a private equity partner to market leading companies in software, data analytics and software-enabled technology services sectors. The firm brings expertise, flexibility, and resources to build strategic value and unlock the potential of innovative companies. Partnering to build customer-centric, market leading portfolio companies, STG seeks to create sustainable foundations for growth that bring value to its companies. The firm is dedicated to transforming and building outstanding technology companies in partnership with leading management teams. STG and its predecessor, Symphony Technology Group (“Symphony”), have managed approximately $6 billion in total capital. For more information, please visit stgpartners.com
Kantar Reputation Intelligence – The leader in earned media tracking and measurement in Europe. Reputation Intelligence provides trusted insights on corporate, PR and brand coverage in 130+ markets to brands can understand and manage how audiences and influencers see them, globally and locally.
Onclusive – Empowers the world’s leading brands and agencies to modernize communications, increase performance and demonstrate value. The inventors of PR Attribution™ and Power of Voice™, Onclusive measures the true impact of earned, owned and social content on a company’s bottom line.
PRgloo – The complete media relations platform. PRgloo combines easy to use tools with exceptional analysis to make PR professionals’ lives easier by giving them the tools they need to do their jobs well.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005044/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom